Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early HLA Matched Sibling HSCT for Children With Sickle Cell Disease (STAR)
NCT04018937Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Mar 2019
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of alemtuzumab, fludarabine, melphalan in sickle cell disease (SCD), sponsored by Emory University. Started Mar 2019; status: active, not recruiting.
02
Drugs
alemtuzumabfludarabinemelphalan
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04018937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018937.